1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Darzalex Solid Tumor And PD-(L)1 Combo Future Dashed

 
• By Eleanor Malone

Hopes for Genmab/Janssen's myeloma drug daratumumab in solid tumors have faded after the CALLISTO trial in combination with Roche's Tecentriq in NSCLC was halted for lack of benefit and increased mortality. The future is dim for Darzalex in combination with PD-(L)1 therapies in general.

ship wrecked
Darzalex has run aground in PD-(L)1 combos and solid tumors • Source: Shutterstock

Janssen Biotech Inc. has halted a Phase Ib/II study of the marketed multiple myeloma drug Darzalex (daratumumab) in combination with Roche's PD-L1 inhibitor Tecentriq (atezolizumab) in non-small cell lung cancer, on the recommendation of the Data Monitoring Committee (DMC). The company has also stopped a Phase I study of the CD38-targeting antibody with an in-house PD-1 inhibitor in multiple myeloma, and is in touch with other partners to discuss ceasing enrollment and dosing of other studies combining Darzalex with anti-PD-(L)1 agents while the data are being investigated. Health authorities have also been informed.

The CALLISTO/LUC2001 trial of Darzalex and Tecentriq was stopped after the DMC noted both a lack of benefit and increased...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

More from R&D

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 
• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.